This review outlines the evolution of effector-cell-engaging bsAb formats, such as BiTEs, DARTs, TandAbs and IgG-like constructs, along with engineering strategies to enhance Fc function, valency, half-life, safety and efficacy.
A. Gholap, P. Khuspe, Darshana Morankar et al.· Drug Discovery Today· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.